SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is highly active amid discussions surrounding a Department of Justice criminal probe into Fed Chair Jerome Powell, which he has publicly portrayed as political pressure impacting the Federal Reserve's independence. This has ignited heated debate within the community, with some anticipating significant market instability and a potential shift to safe-haven assets, while others see it as a push for faster rate cuts and a challenge to the Fed's authority.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors assess the implications of a proposed cap on credit card interest rates, sparking debate about its potential impact across the fintech lending landscape. The community is actively discussing whether this could create a significant opportunity for SoFi's personal loan segment if traditional banks adjust their credit offerings, or if it poses a challenge, with many believing the cap's passage remains unlikely.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ faces intense market scrutiny as a DOJ subpoena for Fed Chair Jerome Powell fuels uncertainty around central bank independence and broader economic policy. Community sentiment is sharply divided, with concerns about political interference and upcoming credit card rate caps contrasted by persistent "buy the dip" conviction in technology and growth stocks.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following strong visibility at CES, where it showcased advanced agentic voice and visual AI solutions and announced new partnerships in automotive and robotics. The community is highly engaged, discussing the company's significant growth potential from its proprietary white-label technology and high short interest, despite some recent analyst downgrades.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending amidst intense takeover speculation, notably involving Eli Lilly, following compelling Phase 3 data for its ulcerative colitis drug, obefazimod. The community is buzzing with discussions about potential significant acquisition offers and the drug's blockbuster market potential, positioning ABVX as a highly sought-after biotech asset. This M&A interest is further amplified by strong analyst confidence in obefazimod's differentiated profile within the competitive inflammatory bowel disease sector.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings (ANPA), a microcap Hong Kong-based company, is generating significant buzz following news of its acquisition of TikTok icon Khaby Lame's core company and a recent private placement. The community is highly divided, with many drawing parallels to past 'China pump' stocks, anticipating a massive short squeeze while others caution about the stock's extreme valuation and speculative nature.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is drawing significant attention following its preliminary quarterly and full-year results, which reportedly surprised the market with strong revenue and improved adjusted EBITDA. The community is actively debating whether these positive developments, coupled with substantial insider buying and a notably low share float, signal a potential short squeeze or if lingering concerns about the company's cash position and dilution risks will temper sustained upside.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is generating significant buzz as major competitors, including Amazon Pharmacy, expand into the GLP-1 weight loss market with competitively priced oral treatments, intensifying bearish concerns about market share and HIMS's competitive moat. While many anticipate further declines, a strong contingent of bulls points to the company's vertically integrated "lab moat," personalized healthcare strategy, and international expansion as key long-term differentiators, viewing the current downturn as a prime buying opportunity amidst short squeeze potential.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is surging in conversation as its exceptionally active community passionately champions the "OG meme" narrative of Rage Comics, positioning it as the "foundational meme reset" for an upcoming market cycle. This dedicated base showcases strong conviction, actively building an ecosystem with platforms like RageMaker and RageGames, and urging fellow enthusiasts to "Return to the Memes" and "Rage On" to reclaim leadership in the meme coin space.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant upward momentum after announcing a record total contract value exceeding $1.1 billion for 2025, fueled by data agreements with over 70 pharmaceutical and biotech companies. This major business development highlights the strength of its AI-driven precision medicine platform, sparking widespread community excitement and further institutional interest in its role in advancing drug discovery and development.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Hepion Pharmaceuticals Inc. drew heightened attention from retail traders on Monday after the company disclosed that the Nasdaq Hearings Panel had ordered its delisting, citing violations of continued listing requirements.&nbsp;Trading in the company's common stock is set to be suspended at the open on Tuesday, with shares expected to move to the OTC Markets under the same ticker, HEPA.Hepion Pharmaceuticals shares closed down 18.8% at $0.32 on Monday, sliding 45% to $0.17 in after-hours trading.Retail sentiment on Stocktwits turned 'bullish' on Monday amid a 5,100% surge in 24-hour message volume.One user highlighted optimism around Hepion's core asset, Rencofilstat, describing it as a potentially "revolutionary" drug class.&nbsp;Rencofilstat is a cyclophilin inhibitor aimed at treating chronic liver diseases like NASH and hepatocellular carcinoma (HCC).The user suggested that although trial results may not be released soon, the drug could eventually displace existing therapies once they have been fully monetized.&nbsp;They added that the move to OTC "could get interesting."<stembedurl>https://stocktwits.com/BADBOYROY/message/614371348</stembedurl>Another user hoped the stock would be tradable on Robinhood after moving to the OTC market, suggesting the transition could trigger a strong upward move.<stembedurl>https://stocktwits.com/stock_trafficking/message/614386549</stembedurl>The delisting followed Nasdaq's determination that Hepion had failed to maintain the minimum bid price of $1.00 and was in breach of Rule 5101, which allows delisting of companies identified as public shells.Hepion recently entered a license agreement with New Day Diagnostics LLC to distribute tests for celiac disease, respiratory multiplex (COVID-19, Influenza A/B, RSV), H. pylori, and hepatocellular carcinoma (HCC).&nbsp;These tests carry CE marks, making them eligible for sale in Europe.The company had previously paused and then wound down its ASCEND-NASH Phase 2b trial for Rencofilstat, after enrolling 151 patients out of a planned 336.&nbsp;Approximately 80 patients completed a full year of treatment.The stock has declined 98.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Hepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting'

Despite a sharp decline in stock price, retail traders are optimistic about the company's potential, citing its core asset Rencofilstat and speculating on a rebound following the OTC transition.

Equity

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Morristown, NJ.

Hepion Pharmaceuticals Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

HEPA
Hepion Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest HEPA News

HEPAHepion Pharmaceuticals Inc